New drug AGA2118 tested in healthy volunteers across ethnic groups
NCT ID NCT07361354
First seen Jan 27, 2026 · Last updated Jun 22, 2026 · Updated 20 times
Summary
This early-stage study is testing a single dose of a drug called AGA2118 in 30 healthy adults of Japanese, Chinese, and Caucasian backgrounds. Researchers want to see how the drug moves through the body and if it causes any side effects. The goal is to gather basic safety and dosing information, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Los Angeles EPCU
RECRUITINGGlendale, California, 91206, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AGA2118
What this could lead to
If successful, this study could help determine the right dosing for future trials of AGA2118 in different ethnic groups.
What could go wrong
This is an early Phase 1 study in healthy volunteers, not patients. It focuses on drug levels and safety, not on treating any disease. Results may not predict effectiveness in patients.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.